Embecta Corp. (NASDAQ:EMBC – Get Rating) saw a large decrease in short interest in December. As of December 30th, there was short interest totalling 3,900,000 shares, a decrease of 5.8% from the December 15th total of 4,140,000 shares. Based on an average daily volume of 643,400 shares, the short-interest ratio is currently 6.1 days. Approximately 6.9% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, Morgan Stanley cut shares of Embecta from an “equal weight” rating to an “underweight” rating and set a $28.00 target price on the stock. in a research report on Friday, January 6th.
Embecta Trading Down 3.3 %
Shares of EMBC stock opened at $23.70 on Wednesday. Embecta has a fifty-two week low of $22.30 and a fifty-two week high of $49.00. The stock has a 50 day moving average price of $28.89 and a two-hundred day moving average price of $29.54.
Embecta Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 11th. Investors of record on Friday, December 30th were paid a $0.15 dividend. The ex-dividend date of this dividend was Thursday, December 29th. This represents a $0.60 annualized dividend and a dividend yield of 2.53%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Embecta during the third quarter valued at approximately $258,676,000. Vanguard Group Inc. bought a new position in Embecta in the 3rd quarter worth $197,911,000. State Street Corp purchased a new stake in shares of Embecta in the 3rd quarter worth about $68,114,000. Yacktman Asset Management LP bought a new stake in shares of Embecta during the 3rd quarter valued at about $66,598,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Embecta during the third quarter valued at about $29,545,000. Institutional investors own 93.45% of the company’s stock.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
- Get a free copy of the StockNews.com research report on Embecta (EMBC)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.